dksh expands Malaysia push with novasina strategic alliance

KUALA LUMPUR, 28 SEPTEMBER 2026 —

DKSH announced a strategic alliance with Novasina to deepen its market‑expansion services in Malaysia, aiming to broaden the distribution of high‑quality pharmaceutical and performance‑materials products across the country.

The partnership will see DKSH leverage its 160‑year legacy of distributing multinational brands to introduce Novasina’s specialty chemicals and pharma solutions to a wider network of Malaysian customers, according to the company’s press release. DKSH said the alliance aligns with its purpose of enriching people’s lives by bringing innovative products to local markets.

Founded in Penang in 1923, DKSH is one of Malaysia’s oldest market‑expansion service providers. The firm operates a nationwide footprint that includes facilities in Selangor, Johor, Kedah, Perak, Terengganu, Sabah, Sarawak and the Federal Territory, as listed in its corporate address register. Its extensive logistics and regulatory expertise is expected to accelerate Novasina’s entry into sectors such as healthcare, consumer goods and industrial applications.

Novasina, a global specialty chemicals player, will rely on DKSH’s sales, marketing and regulatory teams to navigate Malaysia’s complex approval processes and to reach end‑users in both urban and regional markets. The alliance is part of DKSH’s broader strategy to expand its pharma and performance‑materials divisions, which have shown steady growth in recent quarters.

While the announcement did not disclose financial terms, DKSH highlighted that the collaboration will create new revenue streams and enhance its service portfolio for existing multinational clients. Analysts covering the company will watch for the impact on DKSH’s quarterly earnings and whether the alliance drives higher market share in the fast‑growing Malaysian pharma sector.

The move underscores DKSH’s commitment to deepening its local presence and capitalising on Malaysia’s expanding demand for specialty chemicals and pharmaceutical products. The company will roll out joint go‑to‑market initiatives over the next six months, with further updates expected in its upcoming interim report.